Trial reportPloS one2013
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04979546 (Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic burden of multiple sclerosis in the United States: A systematic literature review.Journal of managed care & specialty pharmacy · 2023Pooled it
- Pooled it
- Cost of Illness of Multiple Sclerosis - A Systematic Review.PloS one · 2016Pooled it
- Trial
- Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Trial
- Explainable artificial intelligence on safe balance and its major determinants in stroke patients.Scientific reports · 2024Article
- Evaluating the impact of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a study protocol for a randomized controlled trial.BMC neurology · 2023Article
- Cerebellar Contributions to Motor Impairments in People with Multiple Sclerosis.Cerebellum (London, England) · 2022Review
- Article
- Functional Electrical Stimulation Cycling Exercise for People with Multiple Sclerosis.Current treatment options in neurology · 2019Review
- Effects of Muscle Function and Limb Loading Asymmetries on Gait and Balance in People With Multiple Sclerosis.Frontiers in physiology · 2018Review
- Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.Multiple sclerosis (Houndmills, Basingstoke, England) · 2017Article
- Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study.Degenerative neurological and neuromuscular disease · 2017Article
- Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study.PharmacoEconomics · 2016Article
- Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2015Article
- Social participation in patients with multiple sclerosis: correlations between disability and economic burden.BMC neurology · 2014Article
- Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis.Cell medicine · 2014Article
- The MoSt Project--more steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy.Journal of neurology · 2014Article
- An Exploratory Study of Community Mobility in Adults With Multiple Sclerosis Across Different Ambulation Levels.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was conducted to estimate the indirect costs and health-related quality of life (HRQoL) (utilities) of multiple sclerosis (MS) patients in the United States (US), and to determine the impact of worsening mobility on these parameters. In collaboration with the North American Research Committee on Multiple Sclerosis (NARCOMS) registry we conducted a cross-sectional study of participants who completed the biannual update and supplemental spring 2010 survey. Demographic, employment status, income, mobility impairment, and health utility data were collected from a sample of registry participants who met the study criteria and agreed to participate in the supplemental Mobility Study. Mean annual indirect costs per participant in 2011US$ and mean utilities for the population and for cohorts reporting different levels of mobility impairment were estimated. Analyses included 3,484 to 3,611 participants, based on survey completeness. Thirty-seven percent of registrants were not working or attending school and 46.7% of these reported retiring early. Indirect costs per participant per year, not including informal caregiver cost, were estimated at $30,601±31,184. The largest relative increase in indirect costs occurred at earlier mobility impairment stages, regardless of the measure used. Participants' mean utility score (0.73±0.18) was lower than that of a similarly aged sample from the general US population (0.87). As with indirect costs, larger decrements in utility were seen at earlier mobility impairment stages. These results suggest that mobility impairment may contribute to increases in indirect costs and declines in HRQoL in MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.